Terms: = Prostate cancer AND ZFHX3, ATBT, 463, ENSG00000140836, Q15911
111 results:
1. SGLT2 inhibition and three urological cancers: Up-to-date results.
Lin L; Ning K; Xiang L; Peng L; Li X
Diabetes Metab Res Rev; 2024 Mar; 40(3):e3797. PubMed ID: 38523292
[TBL] [Abstract] [Full Text] [Related]
2. Lifetime exposure to unemployment and prior working conditions are associated with retiree's health: A retrospective study in a large population-based French cohort.
Sanchez Rico M; Plessz M; Airagnes G; Wiernik E; Hoertel N; Goldberg M; Zins M; Meneton P
Soc Sci Med; 2024 Jan; 341():116550. PubMed ID: 38160610
[TBL] [Abstract] [Full Text] [Related]
3. Cost-Effectiveness Analysis for Therapy Sequence in Advanced cancer: A Microsimulation Approach with Application to Metastatic prostate cancer.
Handorf EA; Beck JR; Correa A; Ramamurthy C; Geynisman DM
Med Decis Making; 2023; 43(7-8):949-960. PubMed ID: 37811793
[TBL] [Abstract] [Full Text] [Related]
4. Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer biochemical recurrence.
Hou Y; Jiang KW; Wang LL; Zhi R; Bao ML; Li Q; Zhang J; Qu JR; Zhu FP; Zhang YD
Br J Cancer; 2023 Nov; 129(10):1625-1633. PubMed ID: 37758837
[TBL] [Abstract] [Full Text] [Related]
5. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.
Wen XY; Wang RY; Yu B; Yang Y; Yang J; Zhang HC
Sci Rep; 2023 Sep; 13(1):15597. PubMed ID: 37730847
[TBL] [Abstract] [Full Text] [Related]
6. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant prostate cancer Detection Rate? A Systematic Review and Meta-analysis.
Uleri A; Baboudjian M; Tedde A; Gallioli A; Long-Depaquit T; Palou J; Basile G; Gaya JM; Sanguedolce F; Lughezzani G; Rajwa P; Pradere B; Roupret M; Briganti A; Ploussard G; Breda A
Eur Urol Oncol; 2023 Dec; 6(6):621-628. PubMed ID: 37634971
[TBL] [Abstract] [Full Text] [Related]
7. Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects.
Ito S; Liu X; Ishikawa Y; Conti DD; Otomo N; Kote-Jarai Z; Suetsugu H; Eeles RA; Koike Y; Hikino K; Yoshino S; Tomizuka K; Horikoshi M; Ito K; Uchio Y; Momozawa Y; Kubo M; ; Kamatani Y; Matsuda K; Haiman CA; Ikegawa S; Nakagawa H; Terao C
Nat Commun; 2023 Aug; 14(1):4863. PubMed ID: 37612283
[TBL] [Abstract] [Full Text] [Related]
8. Unique Spectrum of Activating BRAF Alterations in prostate cancer.
Chehrazi-Raffle A; Tukachinsky H; Toye E; Sivakumar S; Schrock AB; Bergom HE; Ebrahimi H; Pal S; Dorff T; Agarwal N; Mahal BA; Oxnard GR; Hwang J; Antonarakis ES
Clin Cancer Res; 2023 Oct; 29(19):3948-3957. PubMed ID: 37477913
[TBL] [Abstract] [Full Text] [Related]
9. Explainable artificial intelligence to predict and identify prostate cancer tissue by gene expression.
Ramírez-Mena A; Andrés-León E; Alvarez-Cubero MJ; Anguita-Ruiz A; Martinez-Gonzalez LJ; Alcala-Fdez J
Comput Methods Programs Biomed; 2023 Oct; 240():107719. PubMed ID: 37453366
[TBL] [Abstract] [Full Text] [Related]
10. Somatic and Germline Variants Affect Prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
11. PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer.
Scheinberg T; Lin HM; Fitzpatrick M; Azad AA; Bonnitcha P; Davies A; Heller G; Huynh K; Mak B; Mahon K; Sullivan D; Meikle PJ; Horvath LG
Prostate Cancer Prostatic Dis; 2024 Mar; 27(1):136-143. PubMed ID: 37147359
[TBL] [Abstract] [Full Text] [Related]
12. Machine learning-based radiomics model to predict benign and malignant PI-RADS v2.1 category 3 lesions: a retrospective multi-center study.
Jin P; Shen J; Yang L; Zhang J; Shen A; Bao J; Wang X
BMC Med Imaging; 2023 Mar; 23(1):47. PubMed ID: 36991347
[TBL] [Abstract] [Full Text] [Related]
13. Robotic-assisted Simple prostatectomy: An Intrafascial Approach for a prostate of 470 g.
Poncel J; Celis V; Sayegh AS; Eppler M; Medina LG; Sotelo R
Urology; 2023 Jun; 176():246-247. PubMed ID: 36965818
[TBL] [Abstract] [Full Text] [Related]
14. Long-term risk of cancer among the first-degree relatives of epithelial ovarian cancer patients: A cohort study with 48 years of follow up.
Kotaniemi-Talonen L; Pukkala E; Aittomäki K; Auranen A
Acta Obstet Gynecol Scand; 2023 Mar; 102(3):240-245. PubMed ID: 36645194
[TBL] [Abstract] [Full Text] [Related]
15. Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer.
Liu LL; Zhu LL; Lu ZG; Sun JD; Zhao J; Wang HF; Xiang ZL
Cancer Imaging; 2023 Jan; 23(1):1. PubMed ID: 36600283
[TBL] [Abstract] [Full Text] [Related]
16. Health-related quality of life in patients newly diagnosed with prostate cancer: CAPLIFE study.
Lozano-Lorca M; Barrios-Rodríguez R; Redondo-Sánchez D; Cózar JM; Arrabal-Martín M; García-Caballos M; Salcedo-Bellido I; Sánchez MJ; Jiménez-Moleón JJ; Olmedo-Requena R
Qual Life Res; 2023 Apr; 32(4):977-988. PubMed ID: 36409391
[TBL] [Abstract] [Full Text] [Related]
17. Association of triglyceride levels and prostate cancer: a Mendelian randomization study.
Zhu S; Hu X; Fan Y
BMC Urol; 2022 Oct; 22(1):167. PubMed ID: 36316671
[TBL] [Abstract] [Full Text] [Related]
18. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
Liu J; Tan Z; Yang S; Song X; Li W
Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
[TBL] [Abstract] [Full Text] [Related]
19. cancer mortality in the State of Mato Grosso from 2000 to 2015: temporal trend and regional differences.
Modesto VC; Evangelista FM; Soares MR; Alves MR; Neves MABD; Corrêa MLM; Sousa NFDSE; Galvão ND; Andrade ACS
Rev Bras Epidemiol; 2022; 25(Supl 1):e220005. PubMed ID: 35766762
[TBL] [Abstract] [Full Text] [Related]
20. prostate cancer upgrading and adverse pathology in Hispanic men undergoing radical prostatectomy.
Hougen HY; Iakymenko OA; Punnen S; Ritch CR; Nahar B; Parekh DJ; Kryvenko ON; Gonzalgo ML
World J Urol; 2022 Aug; 40(8):2017-2023. PubMed ID: 35689106
[TBL] [Abstract] [Full Text] [Related]
[Next]
